Introduction {#s1}
============

A pneumonia caused by a novel coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), spread rapidly throughout worldwide in December 2019 ([@B1]). Despite progress made in our understanding of the characteristics of the disease, there are currently no drugs to combat SARS-CoV-2, and patients are primarily provided with supportive treatment. Several studies have indicated that the main symptoms of coronavirus disease 2019 (COVID-19) include fever, cough, and dyspnea ([@B2]--[@B5]). Huang et al. described the epidemiological, clinical, laboratory, and radiological characteristics of COVID-19, as well as various treatment strategies and outcomes, among 41 patients during the first wave of hospitalizations. They also compared clinical characteristics between patients treated in an intensive care unit (ICU) and those treated in non-ICU ([@B2]). Yang et al. also performed a detailed analysis of the patients critically ill with SARS-CoV-2 infection ([@B5]). In an analysis of 74 patients with COVID-19 exhibiting gastrointestinal symptoms, Jin et al. suggested that non-classical symptoms have been overlooked, posing a threat to the public ([@B6]). Wu et al. further noted that the risk of acute respiratory distress syndrome (ARDS) and death is increased in older adults (≥65 years old) with COVID-19 ([@B7]). Guo et al. found that diabetes is a risk factor for patients with COVID-19 ([@B8]). However, few prospective studies have explored the short-term outcomes of severely ill patients under current medical treatment and the risk factors that affect the short-term outcomes of severely ill patients, especially pneumonia patients with certain chronic diseases, which accounted for the majority of deaths. Here, we used a single-centered, prospective method to describe the basic clinical characteristics and short-term outcomes of severe patients in Union hospital, Wuhan, and we further aimed to explore the potential risk factors for poor outcomes among these patients using Cox proportional hazard models.

Methods {#s2}
=======

Study Design and Participants
-----------------------------

This single-center, prospective study included 114 severe patients with confirmed COVID-19 pneumonia hospitalized at the Union Hospital in Wuhan, China, which is a hospital designated to treat patients with COVID-19. From January 23, 2020, to February 22, 2020, we continuously enrolled patients diagnosed with COVID-19 based on interim guidance provided by the World Health Organization (WHO). Based on the Diagnosis and Treatment Scheme for SARS- CoV-2 of Chinese (The Seven Edition), severe patients were diagnosed if one or more of following criteria were met: dyspnea with respiratory rate (RR) ≥30 times/min, resting finger oxygen saturation ≤93%, and artery PaO~2~/FiO~2~ ≤300 mm Hg (1 mm Hg = 0.133 kPa). This study was approved by the Ethics Commission of Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was waived due to the emergency of this infectious diseases.

Data Collection
---------------

Data related to clinical characteristics were collected using a case record form modified from the standardized International Severe Acute Respiratory and Emerging Infection Consortium case report form. Epidemiological and demographic data, including age, sex, and coexisting disorders, were also collected. The Baseline laboratory indices and radiographic findings were obtained from clinical electronic medical records. Moreover, the treatment strategies and outcomes were collected until the day of death /discharge or for the first 28 days after a diagnosis of severe illness, whichever was shorter. All missing or vague data, were obtained by communicating with patients and their families. All data were checked by two physicians (Xiaobo Feng and Liang Ma), and a third researcher (Wei Yang) adjudicated any difference in interpretation between the two primary reviewers.

Outcomes
--------

Clinical outcomes after 28 days of consecutive observations were divided into two categories. Patients that had been discharged, those whose condition had been deemed non-severe, and those not requiring mechanical ventilation were considered to have experienced good outcomes. Patients requiring mechanical ventilation and those who had died were considered to have experienced poor outcomes. The criteria for discharge were as follows: normal temperature for more than 3 days (T \< 37.3°C), significant improvement in respiratory symptoms, pulmonary imaging showing significant improvement in acute exudative lesions, and nucleic acid tests negative for respiratory tract specimens such as sputum and nasopharyngeal swabs for two consecutive samplings (at least 24 h after sampling). Patients with mild clinical symptoms and no signs of pneumonia on radiography were considered to be non-severe. ARDS and shock were confirmed by the WHO guidance for COVID-19. Acute kidney injury was defined according to the serum creatinine. Cardiac injury was identified by the serum concentration of hypersensitive cardiac troponin I (hsTNI) and, if it was above the upper limit of the reference range (\>28 pg/mL), measured in the laboratory of Union Hospital ([@B5]).

Statistics
----------

Continuous variables were expressed as means ± SDs if normally distributed and medians (IQRs) if skewed distributed while categorical variables were summarized as number (%). Differences between the characteristics of outcome groups were assessed using students *t*-test or Mann-Whitney U-test for continuous variables and chi-square tests for categorical variables. In addition, univariate and multivariate Cox proportional hazard models were used to determine hazard ratios (HRs) and 95% confidence intervals (CIs) of poor outcome in severe patients with COVID-19. The candidate risk factors included demographic and epidemiological characteristics as well as some laboratory indices. We determined the cut points of levels according to normal range, actual distribution, and clinical significance of each index. Adjustments were made for potential confounders, including age and sex. For risk factors identified in Cox analyses, we used restricted cubic spline model to further explore the potential dose-response relationship between factors and poor outcome risk. The referent (HR = 1) was set according to the cut point in Cox analyses. *P* \< 0.05 was considered statistically significant. All data were analyzed using SPSS (23.0 IBM SPSS).

Results {#s3}
=======

Clinical Outcomes
-----------------

As of March 21, 2020, a total of 114 patients diagnosed with and treated for severe COVID-19 were enrolled in this study. Twenty-eight days after a diagnosis of severe COVID-19, good and poor outcomes were observed in 94 and 20 patients, respectively. As shown in [Figure 1](#F1){ref-type="fig"}, 51 (45%) patients were alive and had been discharged, 39 (34%) had transitioned to non-severe illness, four (3%) remained severely ill but did not require a ventilator, i.e., severe status and ventilator free, 11 (10%) were alive but remained ventilated, and nine (8%) had died.

![Distribution of short-term (28 days) outcomes of severely ill patients with COVID-19 (*N* = 114).](fmed-07-00491-g0001){#F1}

Demographics and Characteristics
--------------------------------

The general demographic and epidemiological characteristics of all enrolled patients are summarized in [Table 1](#T1){ref-type="table"}. The mean age was 63.96 ± 13.41 years, 62 (54.4%) were older than 65 years and 71 (62.3%) were male. A total of 89 (78.1%) severe patients have a chronic medical illness, and the most coexisting disorders were hypertension with 62 (54.4%), diabetes with 39 (34.2%) and cardiovascular disease with 31 (27.2%). No significant differences were observed in such characteristics between outcome groups (*P* ≥ 0.05 for all). [Table 2](#T2){ref-type="table"} displays the clinical characteristics of the patients. The duration from onset of symptoms to diagnosis of COVID-19 was 4.0 (2.0--7.0) days, while the duration from the onset of symptoms to the diagnosis of severe illness was 10.0 (6.0--14.3) days. For 114 patients, the most common symptoms at initial diagnosis were fever in 78 (68.4%), cough in 49 (43.0%), chest tightness in 34 (29.8%), and fatigue in 30 (26.3%) patients. Other symptoms, including shortness of breath in 18 (15.8%), anorexia in 12 (10.5%), chill in 12 (10.5%), myalgia in 10 (8.8%), sputum in nine (7.9%), headache in eight (7.0%), diarrhea in eight (7.0%), chest pain in three (2.6%), stomachache in three (2.6%) and nausea in three (2.6%) were relatively rare. As for oxygen saturation, patients in the poor outcome group had significantly lower levels than those in the good outcome group \[median (IQR): 91 (90--93%) in the good outcome group and 81 (74--88%) in the bad outcome group, *P* \< 0.001\].

###### 

Demographic and epidemiological characteristics of severe patients with COVID-19.

                                          **Total (*N =* 114)**   **Good outcome (*N =* 94)**   **Poor outcome (*N =* 20)**   ***P***
  --------------------------------------- ----------------------- ----------------------------- ----------------------------- ---------
  Age (years)                             63.96 ± 13.41           62.85 ± 13.65                 69.15 ± 11.08                 0.056
  \<65                                    52 (45.6)               46 (48.9)                     6 (30.0)                      0.123
  ≥65                                     62 (54.4)               48 (51.1)                     14 (70.0)                     
  Sex, male                               71 (62.3)               58 (61.7)                     13 (65.0)                     0.782
  Hospital infection                      7 (6.1)                 6 (6.4)                       1 (5.0)                       \>0.999
  Coexisting disorders                    89 (78.1)               73 (77.7)                     16 (80.0)                     \>0.999
  Diabetes                                39 (34.2)               34 (36.2)                     5 (25.0)                      0.339
  Hypertension                            62 (54.4)               50 (53.2)                     12 (60.0)                     0.579
  Hyperlipidemia                          17 (14.9)               15 (16.0)                     2 (10.0)                      0.739
  Cardiovascular diseases                 31 (27.2)               24 (25.5)                     7 (35.0)                      0.388
  Cerebrovascular diseases                6 (5.3)                 3 (3.2)                       3 (15.0)                      0.110
  Cancer                                  10 (8.8)                9 (9.6)                       1 (5.0)                       0.825
  Chronic renal diseases                  6 (5.3)                 4 (4.3)                       2 (10.0)                      0.622
  Chronic liver diseases                  4 (3.5)                 3 (3.2)                       1 (5.0)                       0.543
  Chronic Obstructive Pulmonary Disease   11 (9.6)                9 (9.6)                       2 (10.0)                      \>0.999
  Neuropsychiatric disorders              3 (2.6)                 2 (2.1)                       1 (5.0)                       0.443
  History of surgery                      33 (28.9)               26 (27.7)                     7 (35.0)                      0.511

*Values are n (%) for categorical data, means ± SDs for normally distributed data, or medians (IQRs) for non-normally distributed data*.

###### 

Clinical characteristics of severe patients with COVID-19.

                                                 **Total (*N =* 114)**   **Good outcome (*N =* 94)**   **Poor outcome (*N =* 20)**   ***P***
  ---------------------------------------------- ----------------------- ----------------------------- ----------------------------- ---------
  **Onset of symptom to, d**                                                                                                         
  Diagnosis                                      4.0 (2.0--7.0)          4.0 (2.0--7.0)                4.5 (2.3--10.8)               0.517
  Serious illness                                10.0 (6.0--14.3)        10.0 (6.0--15.0)              8.0 (5.0--14.0)               0.540
  **Signs and symptoms at initial**                                                                                                  
  Fever                                          78 (68.4)               63 (67.0)                     15 (75.0)                     0.486
  Chest tightness                                34 (29.8)               27 (28.7)                     7 (35.0)                      0.577
  Shortness of breath                            18 (15.8)               13 (13.8)                     5 (25.0)                      0.365
  Cough                                          49 (43.0)               39 (41.5)                     10 (50.0)                     0.485
  Sputum                                         9 (7.9)                 8 (8.5)                       1 (5.0)                       0.943
  Fatigue                                        30 (26.3)               28 (29.8)                     2 (10.0)                      0.068
  Headache                                       8 (7.0)                 7 (7.4)                       1 (5.0)                       \>0.999
  Myalgia                                        10 (8.8)                8 (8.5)                       2 (10.0)                      \>0.999
  Chest pain                                     3 (2.6)                 3 (3.2)                       0 (0.0)                       1.000
  Anorexia                                       12 (10.5)               12 (12.8)                     0 (0.0)                       0.198
  Chill                                          12 (10.5)               8 (8.5)                       4 (20.0)                      0.263
  Stomachache                                    3 (2.6)                 3 (3.2)                       0 (0.0)                       \>0.999
  Diarrhea                                       8 (7.0)                 7 (7.4)                       1 (5.0)                       \>0.999
  Nausea                                         3 (2.6)                 2 (2.1)                       1 (5.0)                       0.443
  Temperature at disease onset (°C)              38.1 (36.7--38.8)       38.1 (36.7--38.7)             38.2 (37.0--39.0)             0.561
  \<37.4                                         36 (31.6)               31 (33.0)                     5 (25.0)                      0.622
  37.4--39.0                                     63 (55.3)               50 (53.2)                     13 (65.0)                     
  \>39.0                                         15 (13.2)               13 (13.8)                     2 (10.0)                      
  **Signs and symptoms at hospital admission**                                                                                       
  Fever                                          32 (28.1)               25 (26.6)                     7 (35.0)                      0.448
  Chest tightness                                50 (43.9)               46 (48.9)                     4 (20.0)                      0.018
  Shortness of breath                            68 (59.6)               49 (52.1)                     19 (95.0)                     \<0.001
  Cough                                          9 (7.9)                 7 (7.4)                       2 (10.0)                      \>0.999
  Fatigue                                        43 (37.7)               37 (39.4)                     6 (30.0)                      0.433
  Headache                                       6 (5.3)                 6 (6.4)                       0 (0.0)                       0.542
  Myalgia                                        5 (4.4)                 5 (5.3)                       0 (0.0)                       0.585
  Chest pain                                     3 (2.6)                 3 (3.2)                       0 (0.0)                       \>0.999
  Anorexia                                       18 (15.8)               16 (17.0)                     2 (10.0)                      0.657
  Diarrhea                                       10 (8.8)                7 (7.4)                       3 (15.0)                      0.516
  Nausea                                         2 (1.8)                 2 (2.1)                       0 (0.0)                       \>0.999
  **General signs at admission**                                                                                                     
  Temperature (°C)                               36.7 (36.4--37.4)       36.7 (36.4--37.3)             38.2 (37.0--39.0)             0.279
  \<37.4                                         85 (74.6)               72 (76.6)                     13 (65.0)                     0.535
  37.4--39.0                                     26 (22.8)               20 (21.3)                     6 (30.0)                      
  \>39.0                                         3 (2.6)                 2 (2.1)                       1 (5.0)                       
  Heart rate (/min)                              86 (78--102)            87 (78--102)                  88 (78--102)                  0.456
  \<100                                          83 (72.8)               69 (73.4)                     14 (70.0)                     0.756
  \>100                                          31 (27.2)               25 (26.6)                     6 (30.0)                      
  Respiratory rate (/min)                        20 (20--23)             20 (20--22)                   21 (20--30)                   0.122
  \<20                                           22 (19.3)               19 (20.2)                     3 (15.0)                      0.760
  ≥20                                            92 (80.7)               75 (79.8)                     17 (85.0)                     
  Oxygen saturation (%)                          90 (88--92)             91 (90--93)                   81 (74--88)                   \<0.001
  \<90                                           35 (30.7)               19 (20.2)                     16 (80.0)                     \<0.001
  ≥90                                            79 (69.3)               75 (79.8)                     4 (20.0)                      

*Values are n (%) for categorical data, means ± SDs for normally distributed data, or medians (IQRs) for non-normally distributed data*.

Laboratory and CT Findings
--------------------------

In terms of the 114 severe patients, many laboratory indicators differed significantly between outcome groups ([Table 3](#T3){ref-type="table"}). Compared with the good outcome group, the absolute counts of neutrophils 6.25 (4.69--9.20) vs. 3.48 (2.54--5.23), c-reactive protein 102.15 (78.07--122.90) vs. 48.95 (15.08--83.98), D dimer 2.10 (1.22--3.07) vs. 0.96 (0.41--.78), total bilirubin 19.20 (9.25--33.05) vs. 11.05 (8.53--14.05), blood urea nitrogen 9.02 (5.26--11.30) vs. 4.11 (3.11--5.04), creatine kinase 151.50 (50.50--218.50) vs. 62.00 (46.75--110.50), lactate dehydrogenase 638.00 (436.00--923.00) vs. 259.50 (213.75--382.50), hypersensitive cardiac troponin I 60.70 (18.48--298.98) vs. 4.10 (1.70--10.83), ferritin 679.00 (573.90--993.15) vs. 321.80 (231.00--532.88), interleukin-6 (IL-6) 76.10 (19.05--192.88) vs. 21.23 (7.23--47.61), and IL-10 6.59 (4.58--11.78) vs. 4.64 (3.65--6.18) were significantly higher in poor outcome. Besides, total protein 60.40 (56.78--64.05) vs. 63.80 (59.33--68.50) and PaO2 68.15 (49.00--77.75) vs. 81.00 (74.75--89.00) were significantly lower in poor outcome group. For chest X- ray/CT, 107 (93.9) patients had Ground-glass opacity. These data indicated that the uncontrolled inflammation responses, infection, liver, and kidney dysfunction, and hypoxia may contribute to poor outcomes in patients with COVID-19.

###### 

Laboratory and radiographic findings at baseline of severe patients with COVID-19.

                                                        **Total (*N =* 114)**     **Good outcome (*N =* 94)**   **Poor outcome (*N =* 20)**   ***P***
  ----------------------------------------------------- ------------------------- ----------------------------- ----------------------------- ---------
  **Hematologic**                                                                                                                             
  Leucocytes (×10^9^ /L)                                6.28 ± 3.36               5.74 ± 2.49                   8.78 ± 5.36                   0.022
  Neutrophils (×10^9^ /L)                               3.88 (2.65--5.81)         3.48 (2.54--5.23)             6.25 (4.69--9.20)             \<0.001
  Lymphocytes (×10^9^ /L)                               0.87 (0.65--1.31)         0.92 (0.70--1.43)             0.67 (0.43--0.89)             0.001
  Monocytes (×10^9^ /L)                                 0.44 (0.30--0.59)         0.48 (0.33--0.61)             0.34 (0.22--0.40)             0.009
  Platelets (×10^9^ /L)                                 192.00 (140.74--269.75)   205.00 (142.75--272.50)       165.00 (138.25--218.00)       0.160
  Hemoglobin (g/L)                                      122.04 ± 17.78            122.65 ± 16.75                119.15 ± 22.29                0.427
  CD4+ T cells (%)                                      43.54 (36.45--53.41)      44.98 (36.53--53.20)          39.95 (31.46--57.32)          0.687
  CD8+ T cells (%)                                      21.53 (16.48--28.55)      22.11 (17.61--29.95)          17.90 (14.00--23.45)          0.025
  **Coagulation function**                                                                                                                    
  Prothrombin time (s)                                  13.5 (12.8--14.3)         13.40 (12.70--14.23)          14.25 (12.93--15.28)          0.072
  Activated partial thromboplastin time (s)             38.00 (35.18--41.53)      38.00 (35.10--41.43)          38.45 (35.45--43.98)          0.398
  Fibrinogen (g/L)                                      4.98 ± 1.48               5.05 ± 1.43                   4.66 ± 1.67                   0.282
  Thrombin time (s)                                     17.35 (16.58--18.30)      17.35 (16.77--18.15)          17.20 (15.35--19.18)          0.467
  D-dimer (mg/L)                                        1.06 (0.51--2.10)         0.96 (0.41--1.78)             2.10 (1.22--3.07)             0.005
  **Biochemical**                                                                                                                             
  Alanine aminotransferase (U/L)                        45.50 (26.00--74.25)      44.50 (25.75--72.50)          49.00 (29.25--80.25)          0.427
  Aspartate aminotransferase (U/L)                      39.50 (26.75--64.50)      38.50 (26.00--57.25)          44.00 (29.50--114.75)         0.197
  Total bilirubin (μmol/L)                              11.35 (8.93--16.15)       11.05 (8.53--14.05)           19.20 (9.25--33.05)           0.024
  Total protein (g/L)                                   63.10 (58.48--67.70)      63.80 (59.33--68.50)          60.40 (56.78--64.05)          0.015
  Albumin (g/L)                                         34.65 (30.350--38.60)     35.80 (31.85--39.10)          30.05 (27.10--32.65)          \<0.001
  Globulin (g/L)                                        29.15 (25.70--31.65)      28.95 (25.68--30.78)          30.35 (29.63--35.50)          0.057
  Prealbumin (mg/L)                                     120 (90--153)             120 (90--151)                 93 (82--181)                  0.145
  Blood urea nitrogen (mmol/L)                          4.39 (3.27--6.13)         4.11 (3.11--5.04)             9.02 (5.26--11.30)            \<0.001
  Creatinine (μmol/L)                                   74.35 (60.00--87.85)      74.35 (60.28--86.38)          71.80 (53.70--95.60)          0.636
  Creatine kinase (U/L)                                 66.50 (46.75--133.50)     62.00 (46.75--110.50)         151.50 (50.50--218.50)        0.046
  Creatine kinase-MB (U/L)                              17.00 (14.00--23.00)      17.00 (14.00--22.00)          19.50 (13.00--31.75)          0.234
  Lactate dehydrogenase (U/L)                           286.00 (223.75--452.25)   259.50 (213.75--382.50)       638.00 (436.00--923.00)       \<0.001
  Hypersensitive cardiac troponin I (ng/L)              5.70 (2.10--19.05)        4.10 (1.70--10.83)            60.70 (18.48--298.98)         \<0.001
  Glucose (mmol/L)                                      6.20 (5.20--8.31)         6.13 (5.16--7.63)             8.26 (5.81--13.42)            0.013
  Serum potassium (mmol/L)                              4.03 (3.70--4.50)         4.07 (3.72--4.51)             3.97 (3.59--4.36)             0.344
  Serum sodium (mmol/L)                                 138.85 (136.30--142.00)   138.20 (136.00--141.68)       142.40 (138.85--146.93)       0.001
  Serum calcium (mmol/L)                                2.15 ± 0.18               2.17 ± 0.16                   2.04 ± 0.20                   0.003
  Serum phosphorus (mmol/L)                             1.00 (0.88--1.11)         1.00 (0.89--1.11)             0.95 (0.73--1.12)             0.381
  Serum chlorine (mmol/L)                               100.48 ± 5.10             100.03 ± 4.45                 102.61 ± 7.20                 0.137
  Lactate concentration (mmol/L)                        1.60 (1.38--1.80)         1.50 (1.30--1.70)             2.10 (1.70--2.40)             \<0.001
  Positive Urinary protein, n                           47 (41.2)                 33 (35.1)                     14 (70.0)                     0.004
  Positive Urinary glucose, n                           8 (7.0)                   7 (7.4)                       1 (5.0)                       \>0.999
  Positive urinary occult blood, n                      31 (27.2)                 21 (22.3)                     10 (50.0)                     0.012
  **Blood gas characteristics**                                                                                                               
  pH                                                    7.39 (7.36--7.42)         7.38 (7.36--7.42)             7.41 (7.31--7.46)             0.636
  Arterial partial pressure of oxygen (mm Hg)           79.00 (70.00--88.00)      81.00 (74.75--89.00)          68.15 (49.00--77.75)          \<0.001
  Arterial partial pressure of carbon dioxide (mm Hg)   43.00 (38.00--46.00)      42.80 (38.00--45.00)          45.50 (35.60--57.00)          0.198
  **Infection-related biomarkers**                                                                                                            
  Interleukin 2 (pg/mL)                                 2.70 (2.43--3.04)         2.70 (2.47--3.02)             2.69 (2.41--3.60)             0.991
  Interleukin 4 (pg/mL)                                 2.16 (1.85--2.60)         2.16 (1.89--2.52)             2.21 (1.68--3.50)             0.729
  Interleukin 6 (pg/mL)                                 23.28 (8.31--54.23)       21.23 (7.23--47.61)           76.10 (19.05--192.88)         0.002
  Interleukin 10 (pg/mL)                                4.91 (3.92--6.74)         4.64 (3.65--6.18)             6.59 (4.58--11.78)            0.001
  Tumor necrosis factor-α (pg/mL)                       2.63 (2.11--4.80)         2.63 (2.11--4.80)             2.67 (2.07--4.66)             0.838
  Interferon-γ (pg/mL)                                  2.50 (1.96--3.20)         2.46 (1.96--3.20)             2.58 (1.89--3.49)             0.571
  C-reactive protein (mg/L)                             67.95 (20.50--103.25)     48.95 (15.08--83.98)          102.15 (78.07--122.90)        \<0.001
  Ferritin (ng/mL)                                      390.60 (261.70--721.00)   321.80 (231.00--532.88)       679.00 (573.90--993.15)       0.001
  IgM, *n*                                              60 (68.2)                 52 (69.3)                     8 (61.5)                      0.748
  IgG, *n*                                              88 (100.0)                75 (100.0)                    13 (100.0)                    NA
  **Chest X- ray/CT findings**                                                                                                                
  Ground-glass opacity                                  107 (93.9)                87 (92.6)                     20 (100.0)                    0.351
  Unilateral pneumonia                                  11 (9.6)                  11 (11.7)                     0 (0.0)                       0.208
  Bilateral pneumonia                                   102 (89.5)                82 (87.2)                     20 (100.0)                    0.122
  Interstitial abnormalities                            21 (18.4)                 15 (16.0)                     6 (30.0)                      0.200

*Data are n (%), means ± SDs or medians (IQRs) when appropriate*.

Complications and Treatments
----------------------------

As shown in [Table 4](#T4){ref-type="table"}, patients with severe COVID-19 had complications including acute liver injury, ARDS, acute kidney injury, arrhythmia, acute myocardial injury, Disseminated Intravascular Coagulation (DIC), rhabdomyolysis, and septic shock. However, no patients in the good outcome group experienced septic shock. All patients in the poor outcome group experienced ARDS. Acute myocardial injury, acute kidney injury, arrhythmia, rhabdomyolysis, and DIC were significantly higher than their counterparts in 13.8, 22.3, 17.0, 2.1, and 2.1% of patients with COVID-19 in the good outcome group, respectively. All 114 patients with severe COVID-19 were treated with antibiotics and high flow nasal cannula, while 25 (21.9%) were treated with non-invasive mechanical ventilation and 22 (19.3%) with invasive mechanical ventilation treatment. Six (5.3%) patients were treated with extracorporeal membrane oxygenation (ECMO) and all of whom were in the poor outcome group. Almost all \[113 (99.1%)\] patients received antiviral treatment, including arbidol hydrochloride capsules (0.2 g three times daily), lopinavir, and ribavirin (500 mg two times daily) via the oral route. Furthermore, as many as 41.2% patients received glucocorticoid therapy. Sixty-four (56.1%) patients received immunoglobulin treatment, and 49 (43.0%) patients were treated with parenteral nutrition; the percentage was higher in the poor outcome group than in the good outcome group \[20 (100.0%) vs. 29 (30.9%)\]. Two patients (1.8%) were treated with renal replacement therapy and 20 (17.5%) with vasoconstrictive agents, and it was higher than in the good outcome group \[19 (95.0%) vs. 1 (1.1%)\]. Moreover, the patients were given Traditional Chinese medicine (TCM) based on the protocol ([@B9]). All 20 patients in the poor group were transferred to the ICU, which was significantly higher than that of 9 (9.6%) in the good outcome group.

###### 

Complications and treatments of severe patients with COVID-19.

                                                                       **Total (*N =* 114)**   **Good outcome (*N =* 94)**   **Poor outcome (*N =* 20)**   ***P***
  -------------------------------------------------------------------- ----------------------- ----------------------------- ----------------------------- ---------
  **Complications**                                                                                                                                        
  Shock                                                                8 (7.0)                 0 (0.0)                       8 (40.0)                      \<0.001
  Acute respiratory distress syndrome                                  41 (36.0)               21 (22.3)                     20 (100.0)                    \<0.001
  Acute renal injury                                                   35 (30.7)               21 (22.3)                     14 (70.0)                     \<0.001
  Acute myocardial injury                                              28 (24.6)               13 (13.8)                     15 (75.0)                     \<0.001
  Acute liver function injury                                          69 (60.5)               57 (60.6)                     12 (60.0)                     0.958
  Arrhythmia                                                           31 (27.2)               16 (17.0)                     15 (75.0)                     \<0.001
  Rhabdomyolysis                                                       11 (9.6)                2 (2.1)                       9 (45.0)                      \<0.001
  Disseminated intravascular coagulation                               15 (13.2)               2 (2.1)                       13 (65.0)                     \<0.001
  **Treatment**                                                                                                                                            
  Antibiotic treatment                                                 114 (100.0)             94 (100.0)                    20 (100.0)                    NA
  Anticoronavirus treatment                                            113 (99.1)              93 (98.9)                     20 (100.0)                    \>0.999
  Glucocorticoids                                                      47 (41.2)               28 (29.8)                     19 (95.0)                     \<0.001
  Oxygen therapy                                                       114 (100.0)             94 (100.0)                    20 (100.0)                    NA
  Immunoglobulin                                                       64 (56.1)               45 (47.9)                     19 (95.0)                     \<0.001
  Parenteral nutrition                                                 49 (43.0)               29 (30.9)                     20 (100.0)                    \<0.001
  Admission to intensive care unit                                     29 (25.4)               9 (9.6)                       20 (100.0)                    \<0.001
  Non-invasive ventilation                                             25 (21.9)               13 (13.8)                     12 (60.0)                     \<0.001
  Invasive mechanical ventilation                                      22 (19.3)               4 (4.3)                       18 (90.0)                     \<0.001
  Extracorporeal membrane oxygenation                                  6 (5.3)                 0 (0.0)                       6 (30.0)                      \<0.001
  Vasoconstrictive agents                                              20 (17.5)               1 (1.1)                       19 (95.0)                     \<0.001
  Renal replacement therapy                                            2 (1.8)                 0 (0.0)                       2 (10.0)                      0.029
  Traditional Chinese medicine                                         86 (75.4)               77 (81.9)                     9 (45.0)                      0.001
  Trastuzumab                                                          13 (11.4)               12 (12.8)                     1 (5.0)                       0.459
  Infusions of blood plasma                                            4 (3.5)                 2 (2.1)                       2 (10.0)                      0.141
  **Onset of severe illness to, d[^\*^](#TN1){ref-type="table-fn"}**                                                                                       
  1st for RT-PCR (--)                                                  14.0 (11.0--18.0)       14.0 (10.0--18.0)             19.0 (15.5--24.0)             \<0.001
  2nd for RT-PCR (--)                                                  17.5 (14.0--22.0)       17.0 (14.0--21.5)             24.0 (22.0--27.5)             \<0.001

*Data are n (%) or medians (IQRs) when appropriate*.

*Data available for 98 patients*.

Prediction of Risk Factors for Severe COVID-19 in the Poor Outcome Group
------------------------------------------------------------------------

[Tables 5](#T5){ref-type="table"}, [6](#T6){ref-type="table"} display the results of univariate and multivariate Cox analyses of potential risk factors for short-term outcomes in severe patients with COVID-19. Our results indicated that, for severe patients, higher levels of oxygen saturation (HR, 0.123; 95% CI, 0.041--0.369), albumin (HR, 0.060; 95% CI, 0.008--0.460), and arterial partial pressure of oxygen (HR, 0.321; 95% CI, 0.106--0.973) were associated with decreased risk of developing poor outcome within 28 days. In the other hand, higher levels of leucocytes (HR, 5.575; 95% CI, 2.080--14.943), neutrophils (HR, 2.566; 95% CI, 1.022--6.443), total bilirubin (HR, 6.171; 95% CI, 2.458--15.496), globulin (HR, 2.526; 95% CI, 1.027--6.211), blood urea nitrogen (HR, 5.640; 95% CI, 2.193--14.509), creatine kinase-MB (HR, 3.032; 95% CI, 1.203--7.644), lactate dehydrogenase (HR, 4.607; 95% CI, 1.057--20.090), hypersensitive cardiac troponin I (HR, 5.023; 95% CI, 1.921--13.136), lactate concentration (HR,15.721; 95% CI, 2.099--117.777), Interleukin-10 (HR, 3.551; 95% CI, 1.280--9.857), and C-reactive protein (HR, 5.275; 95% CI, 1.517--18.344) were associated with increased risk of poor outcome development. For all the factors analyzed above, increased concentration of lactate (≥1.6 mmol/L) and total bilirubin (≥19.0 μmol/L) might be the most important predictors of poor outcome in the early stage. As shown in [Figure 2](#F2){ref-type="fig"}, non-linear dose-response relationship was also found between 10 indices and poor outcome risk in the cubic spline model.

###### 

Univariate and multivariate analyses of potential factors (demographic and epidemiologic) predicting poor outcome.

  **Factors**                             **Level**               **Crude HR (95% CI)**   ***P***   **Adjusted HR (95% CI)[^\*^](#TN2){ref-type="table-fn"}**   ***P***
  --------------------------------------- ----------------------- ----------------------- --------- ----------------------------------------------------------- ---------
  Age (years)                             ≥65 vs. \<65            2.192 (0.842--5.708)    0.108     2.184 (0.839--5.687)                                        0.110
  Sex                                     Female vs. Male         0.772 (0.308--1.937)    0.581     0.732 (0.292--1.838)                                        0.507
  Coexisting disorders                    Yes vs. No              1.154 (0.386--3.453)    0.797     0.692 (0.207--2.313)                                        0.550
  Diabetes                                Yes vs. No              0.706 (0.257--1.945)    0.380     0.622 (0.224--1.728)                                        0.363
  Hypertension                            Yes vs. No              1.122 (0.458--2.747)    0.801     0.960 (0.386--2.384)                                        0.929
  Hyperlipidemia                          Yes vs. No              0.677 (0.157--2.919)    0.601     0.729 (0.168--3.167)                                        0.673
  Cardiovascular diseases                 Yes vs. No              1.601 (0.638--4.015)    0.316     1.062 (0.380--2.970)                                        0.908
  Cerebrovascular diseases                Yes vs. No              3.327 (0.975--11.356)   0.055     2.326 (0.612--8.848)                                        0.216
  Cancer                                  Yes vs. No              0.536 (0.072--4.004)    0.543     0.410 (0.054--3.103)                                        0.388
  Chronic renal diseases                  Yes vs. No              3.678 (0.835--16.202)   0.085     3.437 (0.764--15.465)                                       0.108
  Chronic liver diseases                  Yes vs. No              1.433 (0.192--10.707)   0.726     0.997 (0.128--7.760)                                        0.997
  Chronic Obstructive Pulmonary Disease   Yes vs. No              0.991 (0.230--4.272)    0.990     0.642 (0.139--2.955)                                        0.569
  Neuropsychiatric disorders              Yes vs. No              1.186 (0.158--8.894)    0.868     0.734 (0.094--5.741)                                        0.768
  History of surgery                      Yes vs. No              1.168 (0.466--2.930)    0.740     1.041 (0.413--2.623)                                        0.932
  Temperature at disease onset (°C)       37.4--39.0 vs. \<37.4   1.514 (0.540--4.248)    0.430     1.844 (0.638--5.326)                                        0.258
                                          \>39.0 vs. \<37.4       1.036 (0.201--5.342)    0.966     2.714 (0.348--21.190)                                       0.622
  Temperature at admission (°C)           37.4--39.0 vs. \<37.4   1.476 (0.561--3.885)    0.430     1.721 (0.646--4.580)                                        0.277
                                          \>39.0 vs. \<37.4       2.630 (0.343--20.167)   0.352     2.714 (0.348--21.190)                                       0.341
  Respiratory rate (/min)                 ≥20 vs. \<20            1.357 (0.398--4.629)    0.626     1.316 (0.385--4.502)                                        0.662
  Oxygen saturation (%)                   ≥90 vs. \<90            0.131 (0.044--0.394)    \<0.001   0.123 (0.041--0.369)                                        \<0.001

*Adjustments were made for age and sex*.

###### 

Univariate and multivariate analyses of potential factors (laboratory indexes) predicting poor outcome.

  **Factors**                                           **Normal range**   **Level[^†^](#TN3){ref-type="table-fn"}**   **Crude HR (95% CI)**     ***P***   **Adjusted HR (95% CI)[^\*^](#TN4){ref-type="table-fn"}**   ***P***
  ----------------------------------------------------- ------------------ ------------------------------------------- ------------------------- --------- ----------------------------------------------------------- ---------
  **Hematologic**                                                                                                                                                                                                      
  Leucocytes (×10^9^ /L)                                3.5--9.5           ≥9.5 vs. \<9.5                              4.634 (1.840--11.669)     0.001     5.575 (2.080--14.943)                                       0.001
  Neutrophils (×10^9^ /L)                               1.8--6.3           ≥6.3 vs. \<6.3                              2.663 (1.102--6.433)      0.030     2.566 (1.022--6.443)                                        0.045
  Lymphocytes (×10^9^ /L)                               1.1--3.2           ≥1.1 vs. \<1.1                              0.293 (0.068--1.266)      0.100     0.337 (0.077--1.475)                                        0.149
  Monocytes (×10^9^ /L)                                 0.1--0.6           ≥0.6 vs. \<0.6                              0.179 (0.024--1.335)      0.179     0.182 (0.024--1.366)                                        0.098
  Platelets (×10^9^ /L)                                 125.0--350.0       ≥125.0 vs. \<125.0                          0.733 (0.245--2.192)      0.578     0.837 (0.275--2.553)                                        0.755
  Hemoglobin (g/L)                                      130.0--175.0       ≥130.0 vs. \<130.0                          0.865 (0.354--2.116)      0.751     0.652 (0.244--1.732)                                        0.394
  CD4+ T cells (%)                                      25.34--51.37       ≥51.37 vs. \<51.37                          1.144 (0.439--2.980)      0.783     1.235 (0.468--3.259)                                        0.670
  CD8+ T cells (%)                                      14.23--38.95       ≥14.23 vs. \<14.23                          0.687 (0.249--1.890)      0.467     0.867 (0.303--2.482)                                        0.790
  **Coagulation function**                                                                                                                                                                                             
  Prothrombin time (s)                                  11.0--16.0         ≥13.5 vs. \<13.5                            1.574 (0.644--3.852)      0.320     1.112 (0.417--2.966)                                        0.832
  Activated partial thromboplastin time (s)             28.0--43.5         ≥43.5 vs. \<43.5                            1.363 (0.493--3.766)      0.551     1.204 (0.433--3.344)                                        0.722
  Fibrinogen (g/L)                                      2.0--4.0           ≥4.0 vs. \<4.0                              0.533 (0.212--1.338)      0.180     0.520 (0.205--1.317)                                        0.168
  Thrombin time (s)                                     14.0--21.0         ≥17.4 vs. \<17.4                            1.114 (0.463--2.678)      0.809     1.197 (0.489--2.930)                                        0.694
  D-dimer (mg/L)                                        \<0.5              ≥0.5 vs. \<0.5                              1.232 (0.411--3.697)      0.710     0.940 (0.294--3.001)                                        0.917
  **Biochemical**                                                                                                                                                                                                      
  Alanine aminotransferase (U/L)                        5--40              ≥40 vs. \<40                                0.961 (0.393--2.351)      0.931     1.203 (0.429--3.373)                                        0.726
  Aspartate aminotransferase (U/L)                      8--40              ≥40 vs. \<40                                1.611 (0.658--3.942)      0.296     1.900 (0.755--4.783)                                        0.173
  Total bilirubin (μmol/L)                              5.1--19.0          ≥19.0 vs. \<19.0                            5.849 (2.433--14.063)     \<0.001   6.171 (2.458--15.496)                                       \<0.001
  Total protein (g/L)                                   60--80             ≥60 vs. \<60                                0.687 (0.284--1.661)      0.405     0.721 (0.298--1.748)                                        0.470
  Albumin (g/L)                                         35--55             ≥35 vs. \<35                                0.054 (0.007--0.405)      0.054     0.060 (0.008--0.460)                                        0.007
  Globulin (g/L)                                        20--30             ≥30 vs. \<30                                2.723 (1.113--6.666)      0.028     2.526 (1.027--6.211)                                        0.043
  Prealbumin (mg/L)                                     170--420           ≥170 vs. \<170                              1.001 (0.364--2.755)      0.999     1.282 (0.448--3.665)                                        0.643
  Blood urea nitrogen (mmol/L)                          2.9--8.2           ≥8.2 vs. \<8.2                              6.283 (2.565--15.391)     \<0.001   5.640 (2.193--14.509)                                       \<0.001
  Creatinine (μmol/L)                                   44--133            ≥74 vs. \<74                                0.973 (0.405--2.337)      0.950     0.709 (0.254--1.978)                                        0.511
  Creatine kinase (U/L)                                 38--174            ≥174 vs. \<174                              2.039 (0.783--5.307)      0.144     1.982 (0.756--5.199)                                        0.164
  Creatine kinase-MB (U/L)                              0--24              ≥24 vs. \<24                                2.449 (1.000--5.997)      0.050     3.032 (1.203--7.644)                                        0.019
  Lactate dehydrogenase (U/L)                           109--245           ≥245 vs. \<245                              3.963 (0.915--17.161)     0.066     4.607 (1.057--20.090)                                       0.042
  Hypersensitive cardiac troponin I (ng/L)              \<26.2             ≥26.2 vs. \<26.2                            5.613 (2.233--14.112)     \<0.001   5.023 (1.921--13.136)                                       0.001
  Glucose (mmol/L)                                      3.9--6.1           ≥6.1 vs. \<6.1                              1.678 (0.637--4.416)      0.295     1.454 (0.543--3.893)                                        0.457
  Serum potassium (mmol/L)                              3.5--5.2           ≥4.0 vs. \<4.0                              1.112 (0.462--2.677)      0.813     0.921 (0.368--2.304)                                        0.860
  Serum sodium (mmol/L)                                 136--145           ≥136 vs. \<136                              1.881 (0.436--8.120)      0.397     3.302 (0.702--15.535)                                       0.131
  Serum calcium (mmol/L)                                2.03--2.54         ≥2.03 vs. \<2.03                            0.385 (0.160--0.925)      0.033     0.433 (0.173--1.083)                                        0.073
  Serum phosphorus (mmol/L)                             0.96--1.62         ≥0.96 vs. \<0.96                            0.831 (0.345--2.001)      0.680     0.794 (0.330--1.914)                                        0.608
  Serum chlorine (mmol/L)                               96--108            ≥96 vs. \<96                                1.617 (0.375--6.970)      0.519     2.195 (0.489--9.845)                                        0.305
  Lactate concentration (mmol/L)                        0.5--1.6           ≥1.6 vs. \<1.6                              15.457 (2.067--115.615)   0.008     15.721 (2.099--117.777)                                     0.007
  Positive Urinary protein                              /                  /                                           3.239 (1.244--8.433)      0.016     2.905 (1.099--7.678)                                        0.032
  Positive Urinary glucose                              /                  /                                           0.893 (0.120--6.676)      0.912     0.961 (0.128--7.238)                                        0.969
  Positive urinary occult blood                         /                  /                                           2.474 (1.030--5.945)      0.043     2.247 (0.932--5.421)                                        0.071
  **Blood gas characteristics**                                                                                                                                                                                        
  pH                                                    7.35--7.45         ≥7.35 vs. \<7.35                            0.427 (0.170--1.074)      0.071     0.468 (0.181--1.207)                                        0.116
  Arterial partial pressure of oxygen (mm Hg)           80--100            ≥80 vs. \<80                                0.295 (0.098--0.883)      0.029     0.321 (0.106--0.973)                                        0.045
  Arterial partial pressure of carbon dioxide (mm Hg)   35--45             ≥45 vs. \<45                                2.159 (0.892--5.230)      0.088     2.224 (0.895--5.525)                                        0.085
  **Infection-related biomarkers**                                                                                                                                                                                     
  Interleukin-2 (pg/mL)                                 0.1--4.1           ≥4.1 vs. \<4.1                              1.820 (0.533--6.212)      0.339     2.343 (0.654--8.389)                                        0.191
  Interleukin-4 (pg/mL)                                 0.1--3.2           ≥3.2 vs. \<3.2                              1.663 (0.663--4.172)      0.279     2.112 (0.797--5.597)                                        0.133
  Interleukin-6 (pg/mL)                                 0.1--2.9           ≥23.3 vs. \<23.3                            1.782 (0.711--4.468)      0.218     1.485 (0.575--3.836)                                        0.414
  Interleukin-10 (pg/mL)                                0.1--5.0           ≥5.0 vs. \<5.0                              2.629 (1.010--6.843)      0.048     3.551 (1.280--9.857)                                        0.015
  Tumor necrosis factor-α (pg/mL)                       0.1--23.0          ≥2.6 vs. \<2.6                              1.079 (0.448--2.600)      0.866     1.032 (0.427--2.491)                                        0.945
  Interferon-γ (pg/mL)                                  0.1--18.0          ≥2.5 vs. \<2.5                              1.260 (0.522--3.043)      0.607     1.421 (0.582--3.473)                                        0.440
  C-reactive protein (mg/L)                             \<8.0              ≥65.0 vs. \<65.0                            4.703 (1.374--16.093)     0.014     5.275 (1.517--18.344)                                       0.009
  Ferritin (ng/mL)                                      4.6--204.0         ≥204.0 vs. \<204.0                          2.582 (0.210--11.930)     0.657     2.647 (0.311--22.522)                                       0.373

*Adjustments were made for age and sex*.

*Cut points of levels were determined according to normal range, actual distribution, and clinical significance*.

![Non-linear dose--response relationship between 10 indices and poor outcome risk. Hazard ratios (HRs) were adjusted for age and gender. Dotted lines represent the 95% CIs for the fitted trend. **(A)** Leucocytes (×10^9^ /L), referent (HR = 1): 9.5; **(B)** Neutrophils (×10^9^ /L), referent: 6.3; **(C)** Total bilirubin (μmol/L), referent: 19.0; **(D)** Albumin, referent: 35.0 (g/L); **(E)** Globulin (g/L), referent: 30.0; **(F)** Blood urea nitrogen (mmol/L), referent: 8.2; **(G)** CK-MB (U/L), referent: 24.0; **(H)** Lactate dehydrogenase (U/L), referent: 245; **(I)** Hypersensitive cardiac troponin I (ng/L), referent: 26.2; **(J)** Lactate (mmol/L), referent: 1.6.](fmed-07-00491-g0002){#F2}

Discussion {#s4}
==========

The global spread of SARS-CoV-2 poses a significant threat to public health. Previous studies have shown that 20% of COVID-19 patients developed critical disease due to hypoxia or respiratory failure. Among them, 5% require treatment in the ICU, while 15% require oxygen and essential care. This suggests that this is particularly important in understanding this part of the patient ([@B10]). Recently, Dong et al. found that children, particularly infants, developed severe outcomes ([@B11]). This indicated that patients of any age could develop severe illness. Feng et al. found that severe and critical patients with the typical characteristics of multiple organ and immune function dysfunction. They also found that older people aged ≥ 75 years are a risk factor for mortality ([@B12]). With the increase number of asymptomatic infectious patients, taking measures to detect and isolate early are especially important. In our study, we used a short-term method to prospectively study the reported the epidemiology and risk factors of 114 severe patients with COVID-19 from the Union hospital, Hubei province. To our knowledge, this is the first report to describes the severe patients with COVID-19 during a short-term observation and predict some risk factors for final outcome. In our study, the mean age of severe patients were 63.96 ± 13.41 years, and 58 (50.9%) were older than 65 years; the patients are thus older than in other studies ([@B5], [@B13], [@B14]). We also found that 78 (68.4%) of 114 patients initially exhibited fever, in accordance with previous studies, where fever is the one of the most common symptom in patients who had COVID-19 ([@B5], [@B14]--[@B16]). But, 36 (31.6%) of 114 severe patients did not exhibit fever at the beginning of illness, and other clinical manifestations should therefore be concerned. Recently, Jin et al. found that attention should also be paid to people who have gastrointestinal symptoms ([@B6]). Mao et al. indicated that clinicians should suspect COVID-19 also in patients with neurological manifestations ([@B14]).

According to results from laboratory tests, the poor outcome group had lower lymphocytes than the good outcome group \[0.67 (0.43--0.89) vs. 0.92 (0.70--1.43)\]. As is known to all, lymphocytes are the main fighting force against the virus, and we suspected that SARS-CoV-2 damages the lymphocyte and causes its reduction ([@B17]). Chen et al. found that severe lymphopenia were persistent and we more increased in dead patients than recovered patients, and they suggested that lymphopenia may be associated with poor outcome ([@B18]). Tan et al. demonstrated a contrasting result: lymphopenia is an effective indicator for the severity of patients with COVID-19 ([@B19]). CD8+ T cells were significantly lower in the poor outcome group. Chen et al. indicated that the SARS-CoV-2 infection may affect CD4+ and CD8+ T lymphocyte cells in particular and argue that this is a potential correlation with COVID-19 severity ([@B20]). In addition, markedly higher concentrations of cardiac troponin I, creatine kinase, and lactate dehydrogenase could be observed in the poor outcome group than in their counterpart. Most notably, patients who exhibited a poor outcome may develop pulmonary and extra-pulmonary organ damage, including septic shock, acute respiratory distress syndrome, acute kidney injury, acute cardiac injury, as well as disseminated intravascular coagulation. The fatality risk of COVID-19 patients with or without a history of previous cardiovascular disease may include acute cardiac injury and heart failure ([@B18]). Costanza Emanueli et al. suggested that the COVID-19 crisis will have long-term residual repercussions on the cardiovascular system ([@B21]). The suggestion is that the cardiac injury also requires special attention. In our study, we also found that lactate concentration was higher in poor outcomes than their counterpart. Lactate is generally the end product of energy through anaerobic metabolism, and the elevation of lactate levels is mainly caused by the increase of blood oxygen deficiency and anaerobic metabolism; this result is consistent with the lower oxygen saturation in the poor group, and this indicated that lactate level is an important predictor of poor outcome in the early stage. In addition, total bilirubin was also an important predictor of poor outcome in the early stage. Qi recommend that dynamic monitoring of the liver function of patients is necessary ([@B22]). Cai et al. conclude that patients with abnormal liver function may had higher risks of progressing to severe disease ([@B23]). Due to the "cytokine storm" also observed in the poor outcome group, 19 (95.0%) of these patients were given glucocorticoid therapy. Wu et al. previously found that the administration of methylprednisolone may have reduced the risk of death in patients with ARDS ([@B7]). To our surprise, most of the severe patients treated with Traditional Chinese medicine (TCM) were eventually converted to a good outcome, indicating the importance of this effort on COVID-19. A large of clinical practice results indicated that TCM shows significant role in the patients with COVID-19. For the severe patients in the treatment of TCM, the mean length in hospital and the time of nucleic acid turning negative has been shortened by more than 2 days ([@B24]). Yang et al. analyzed the effect of Lian Hua Qing Wen Capsules in the treatment of COVID-19 patients, and they found that this TCM could markedly relieve fever and cough and promote recovery ([@B25]). Besides, a comprehensive evaluation and further scientific research should be carried out on the effect of TCM on COVID-19.

Meantime, the risk factors related to the poor outcome included uncontrolled inflammation responses, infection, hypoxia, and liver, kidney, and cardiac dysfunction. The pathogenesis of COVID-19 is still being studied. Cytokine storms and uncontrolled inflammation responses are thought to play important roles in the outcome of COVID-19 ([@B26]--[@B30]). External stimuli resulted in an excessive immune response, and the pathogenesis of the cytokine storm is complex and can leaded to rapid disease progression and high mortality. The inflammatory cytokine storm is closely correlated to the development and progression of ARDS ([@B31]). Neutrophils play important role in chemokines and cytokines ([@B32]). In our study, the poor outcome group had significantly higher neutrophil counts than the good outcome group, and this may be the underlying cause of the cytokine storm. In addition, CD8^+^ T cells were significantly lower in the poor outcome group. These results highlight the important roles of CD8^+^ T cells in COVID-19. Studies had shown that T cells could inhibit the over-activation of innate immunity ([@B33]). T cells can help to clear SARS-CoV, and a low T-cell response can result in pathological changes in mice with SARS-CoV ([@B34]). The relevant mechanisms need to be studied further.

This study has some limitations. First, owing to the limited number of cases, only 114 severe patients were included. Second, this study was a single-center research, and a larger cohort study of severe patients with SARS-CoV-2 from other cities in China and other countries would help to further describe the clinical characteristics and predict risk factors related to this disease. Third, although we included numerous factors that may be associated with clinical outcome in the analyses and made adjustment for potential confounders when exploring the associations, we could not rule out the possibility of other residual confounders.

In summary, the present study is a single-center, prospective observational study that examined clinical characteristics and risk factors for poor short-term outcomes in patients with severe COVID-19. Our univariate and multivariate analyses demonstrated that cytokine storm/uncontrolled inflammatory responses as well as liver, kidney, and cardiac dysfunction may play important roles in determining final outcomes in patients with severe illness due to COVID-19 infection. Our data may aid clinicians in diagnosing severe cases of COVID-19 and determining the most appropriate treatment strategies for infected patients. Given that Traditional Chinese medicine has been shown to improve outcomes in some cases, additional studies are also required to assess the efficacy of such strategies.

Data Availability Statement {#s5}
===========================

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement {#s6}
================

The studies involving human participants were reviewed and approved by the Ethics Commission of Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology. Written informed consent was waived for the emergency of this infectious disease.

Author Contributions {#s7}
====================

CY and WY designed the study, had full access to all data in the study, and took responsibility for the integrity of data and the accuracy of the data analysis. XF and LM contributed to data collection, literature search, and writing of the manuscript. XF and PL had roles in data analysis and data interpretation. All authors contributed to data acquisition and clinical management, and they reviewed and approved the final version of the manuscript.

Conflict of Interest {#s8}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We thank all the patients and their families involved in this study as well as numerous civilians working together to fight against SARS-CoV-2.

[^1]: Edited by: Longxiang Su, Peking Union Medical College Hospital (CAMS), China

[^2]: Reviewed by: Yanxing Wei, University of Toronto, Canada; Guodong Fu, Mount Sinai Hospital, University of Toronto, Canada

[^3]: This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

[^4]: †These authors have contributed equally to this work and share first authorship
